US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 6946292B2
· Kanda et al.
· 2005
[cited by applicant]
US 7214775B2
· Hanai et al.
· 2007
[cited by applicant]
US 7696222B2
· Wang
· 2010
[cited by applicant]
US 8133899B2
· Mitton-Fry et al.
· 2012
[cited by applicant]
US 8546422B2
· Leblanc et al.
· 2013
[cited by applicant]
US 8637541B2
· Wang
· 2014
[cited by applicant]
US 8759366B2
· Childers et al.
· 2014
[cited by applicant]
US 8790651B2
· Bammert et al.
· 2014
[cited by applicant]
US 8987283B2
· Mitton-Fry et al.
· 2015
[cited by applicant]
US 9206253B2
· Bammert et al.
· 2015
[cited by applicant]
US 20170275369A1
· Bilsborough
· 2017
[cited by applicant]
CN 107683291A
· 2018
[cited by applicant]
EA 009026B1
· 2007
[cited by applicant]
RU 2445318C2
· 2012
[cited by applicant]
RU 2503460C2
· 2014
[cited by applicant]
RU 2588462C2
· 2016
[cited by applicant]
RU 2698907C2
· 2019
[cited by applicant]
WO WO2004085475A2
· 2004
[cited by applicant]
WO WO2004085476A2
· 2004
[cited by applicant]
WO WO2008054606A2
· 2008
[cited by applicant]
WO WO2009062102A2
· 2009
[cited by applicant]
WO WO2010031183A1
· 2010
[cited by applicant]
WO 2010099039A1
· 2010
[cited by applicant]
WO WO2013011407A1
· 2013
[cited by applicant]
WO WO2014039461A1
· 2014
[cited by applicant]
WO 2016156588A1
· 2016
[cited by applicant]
WO 2017102920A1
· 2017
[cited by applicant]
WO WO2017186928A1
· 2017
[cited by applicant]
WO 2018108969A1
· 2018
[cited by applicant]
WO 2018156367A1
· 2018
[cited by applicant]
WO WO2018156180A1
· 2018
[cited by applicant]
WO WO2019200787A1
· 2019
[cited by applicant]
Finkelshtein et al., 2012, “F59 Protein Physics: A Lecture Course with Color and Stereoscopic Illustrations and Problems,” 4th ed., rev. and enl.—Moscow: KDU, 2012, p. 23, in Russian with machine English translation (4 …
[cited by applicant]
Hlavacek et al., 1999, “Steric effects on multivalent ligand-receptor binding: exclusion of ligand sites by bound cell surface receptors,” Biophys. J., 76(6):3031-3043.
[cited by applicant]
Pluckthun et al., 1997, “New protein engineering approaches to multivalent and bispecific antibody fragments,” Immunotechnology, 3(2):83-105.
[cited by applicant]
Roitt et al., 1997, Chapter 9—Antigen Recognition from Immunology, Fifth Edition, Mosby International Ltd, p. 150 in Russian with English translation (8 pages).
[cited by applicant]
World Health Organization (WHO), 2010, International Nonproprietary Names for Pharmaceutical Substances (INN), Recommended International Nonproprietary Names: List 63, WHO Drug Information, vol. 24, No. 1, pp. 41-80.
[cited by applicant]
Deev et al., 2009, “Modern technologies for creating non-natural antibodies for clinical use,” J. of Nat., pp. 32-50, in Russian with machine English translation (38 pages).
[cited by applicant]
Gorshkova et al., 2016, “Evolutionary Plasticity of IL-6 Cytokine Family,” Molecular Biology, 50(6):1039-1048, in Russian with machine English translation (20 pages).
[cited by applicant]
Singer et al., 1998, “Genes and Genomes,” Moscow, Mir, translation from English, 1:63-64, in Russian with machine English translation (8 pages).
[cited by applicant]
Baert et al., Influence of Immunogenicity on the long term efficacy of Infliximab in Crohns disease, New England Journal Med., 2003, pp. 601-608, 348.
[cited by applicant]
Beniaminovitz et al., Prevention of rejection in cardiac transplantation by blockade of the interleukin 2 receptor with a monoclonal antibody, New England Journal of Medicine, 2000, pp. 613-619, 342.
[cited by applicant]
Bergeron et al., Comparative functional characterization of canine IgG subclasses, Veterinary Immunology and Immunopathology, 2014, pp. 31-41, 157.
[cited by applicant]
Chothia and Lesk et al., Canonical Structures for the Hypervariable Regions of Immunoglobins, J. Mol. Biol., 1987, 901-917, 196.
[cited by applicant]
Chothia et al., Conformations of immunoglobin hypervariable regions, Nature, 1989, 877-883, 342.
[cited by applicant]
Gelebart, Pascal and Lai, Raymond, IL22RA1 (interleukin 22 receptor, alpha 1), Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2010, 1106-1110, 14(12).
[cited by applicant]
Ghosh et al., Natalizumab for active Crohns disease, New England J. Med., 2003, pp. 24-32, 348.
[cited by applicant]
Guttman-Yassky, Emma et al., Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double…
[cited by applicant]
Harskamp et al., Immunology of Atopic Dermatitis: Novel Insights into Mechanisms and Immunomodulatory Therapies, Seminars in Cutaneous Medicine and Surgery, 2013, 132-139, 32.
[cited by applicant]
Huber, Samuel et al., IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine, Nature, 2012, 259-263, 491.
[cited by applicant]
Kabat, the Structural Basis of Antibody Complementarity, Adv. Prot. Chem., 1978, 1-75, 32.
[cited by applicant]
Kabat, Unusual Distributions of Amino Acids in Complementarity-determining (Hypervriable) Segment of Heavy and Light Chains of Immunoglobulins and Their Possible Roles in Specificity of Antibody-combining Sites, J. Biol…
[cited by applicant]
Klein, Christian et al., Engineering therapeutic bispecific antibodies using CrossMab technology, Methods, 2019, 21-23, 154.
[cited by applicant]
Klein, Christian et al., The use of CrossMAb technology for the generation of bi- and multispecific antibodies, MABS, 2016, 1010-1020, 8.
[cited by applicant]
Lee, Donna W. et al., Nonclinical safety assessment of a human interleukin-22FC IG fusion protein demonstrates in vitro to in vivo and cross-species translatability, Pharmacol Res Perspect., 2018, 1-13, e00434.
[cited by applicant]
Lipsky et al., Infliximab and methotrexate in the treatment of rheumatoid arthritis, New England Journal of Medicine, 2000, pp. 1594-1602, 343.
[cited by applicant]
Milgrom et al., Treatment of allergic asthma with monoclonal anti IgE antibody, New England Journal Med., 1999, pp. 1966-1973, 341.
[cited by applicant]
Morrison, Sherie L. et al., Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains, Proc. Natl. Acad. Sci. USA, 1984, 6851-6855, 81.
[cited by applicant]
Nuttall et al., Canine Atopic Dermatitis—what have we learned?, Veterinary Record, 2013, 201-207, 172(8).
[cited by applicant]
Rahman et al., The Pathology and Immunology of Atopic Dermatitis, Inflammation & Allergy—Drug Targets, 2011, 486-496, 10.
[cited by applicant]
Ruzicka, Thomas et al., Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis, The New England Journal of Medicine, 2017, 826-835, 376(9).
[cited by applicant]
Schaefer, Wolfgang et al., Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies, PNAS, 2011, 11187-11192, 108.
[cited by applicant]
Shinkawa et al., The absence of fucose but not the presence of galactose or bisecting N acetylglucosamine of human IgG1 complex type oligosaccharide shows the critical role of enhancing antibody dependent cellular cytot…
[cited by applicant]
Slamon et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, New England J. Med., 2001, pp. 783-792, 344.
[cited by applicant]
Tang et al., Cloning and characterization of cDNAs encoding four different canine immunoglobulin Y chains, Veterinary Immunology and Immunopathology, 2001, pp. 259-270, 80.
[cited by applicant]
Xu, Wenfeng et al., A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist, PNAS, 2001, 9511-9516, vol. 98 | No. 17.
[cited by applicant]
Marsella et al., 2012, “Current understanding of the pathophysiologic mechanisms of canine atopic dermatitis,” J. Am. Vet. Med. Assoc., 241(2):194-207.
[cited by applicant]